Literature DB >> 16357730

Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity.

Fernando Perez-Ruiz1, Iñaki Hernando, Irama Villar, Joan M Nolla.   

Abstract

BACKGROUND: Dosing of allopurinol should be corrected depending on renal function, but corrections based on either plasma creatinine (Pcr) or creatinine clearance (CrCl) have been suggested to be minimal standards of care.
METHODS: Data from a cohort database of 484 gouty patients were used to calculate estimated allopurinol doses using CrCl and estimation of the clearance of creatinine using the equation of Cockroft and Gault (CrCl-CG) if, as a hypothesis, a dosage of 300 mg/d would be prescribed in any patient with Pcr <2.0 mg/dL. Also, allopurinol-related toxicity previous to rheumatologic consultation, during previous allopurinol therapy, and the relationship between both and estimated allopurinol doses were reviewed.
RESULTS: The cutoff point of plasma creatinine <2 showed 13% sensitivity and 100% specificity to detect CrCl <50 mL/min. Correlation and agreement between CrCl and CrCl-CG were good, as was the correlation between corrected doses using CrCl and CrCl-CG. One third of patients with Pcr 1.0-1.5 mg/dL and 90% of those with Pcr 1.5-2.0 mg/dL would receive estimated doses over 400 mg/dL/d CrCl. Also, 10% and 34% would receive estimated doses over 600 mg/dL/d CrCl, respectively. Allopurinol-related toxicity previous to consultation (11%) was associated with estimated doses over 400 mg/dL/d CrCl and severe toxicity with estimated doses over 600 mg/dL/d CrCl. When patients were given doses corrected on CrCl, few side effects were observed during follow up (6.7%), and the only severe one was associated with corrected dose over 600 mg/d.
CONCLUSIONS: Dosage adjustment of allopurinol should be based on clearance of creatinine or estimation of glomerular filtration using the Cockcroft-Gault equation. Pcr is insensitive enough to detect renal function impairment so that patients may be placed at risk for overdosing side effects. Corrected doses over 600 mg/dL/d CrCl may be associated with increased risk of severe toxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16357730     DOI: 10.1097/01.rhu.0000164822.98163.22

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  15 in total

1.  [Allopurinol-induced hypersensitivity syndrome resulting in death].

Authors:  Sören Laurisch; Maren Jaedtke; Reyhan Demir; Sajoscha A Sorrentino; Jan T Kielstein; Hans-Oliver Rennekampff; Peter M Vogt; Gerd P Meyer; Martin Fuchs; Gunnar Klein; Hartmut Drexler; Bernhard Schieffer; L Christian Napp
Journal:  Med Klin (Munich)       Date:  2010-04

2.  2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Authors:  Dinesh Khanna; John D Fitzgerald; Puja P Khanna; Sangmee Bae; Manjit K Singh; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

Review 3.  Optimizing current treatment of gout.

Authors:  Frances Rees; Michelle Hui; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2014-03-11       Impact factor: 20.543

Review 4.  Management of gout in older adults: barriers to optimal control.

Authors:  Karl T Hoskison; Robert L Wortmann
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 5.  A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.

Authors:  Jeannie Chao; Robert Terkeltaub
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 6.  Gout. Novel therapies for treatment of gout and hyperuricemia.

Authors:  Robert Terkeltaub
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

7.  Uric Acid nephrolithiasis: recent progress and future directions.

Authors:  Tin C Ngo; Dean G Assimos
Journal:  Rev Urol       Date:  2007

Review 8.  Update on gout: new therapeutic strategies and options.

Authors:  Robert Terkeltaub
Journal:  Nat Rev Rheumatol       Date:  2010-01       Impact factor: 20.543

9.  Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.

Authors:  Fernando Perez-Ruiz; Sandra Pamela Chinchilla; Joana Atxotegi; Irati Urionagüena; Ana Maria Herrero-Beites; Maria Angeles Aniel-Quiroga
Journal:  Rheumatol Int       Date:  2015-09-05       Impact factor: 2.631

10.  Avoidability of adverse drug reactions spontaneously reported to a French regional drug monitoring centre.

Authors:  Annie Pierre Jonville-Béra; Hassan Saissi; Lamiae Bensouda-Grimaldi; Frederique Beau-Salinas; Haware Cissoko; Bruno Giraudeau; Elisabeth Autret-Leca
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.